Clinical Liver Disease
© 2014 The American Association for the Study of Liver Diseases
Recently Published Issues
Current Issue:December 2014
Volume 4, Issue 5
Special Issue: Procedures for the Liver Patient
Volume 4, Issue 4
Special Issue: The Pediatric Liver Patient
Volume 4, Issue 3
Special Issue: Liver Disease in Pregnancy
Volume 4, Issue 2
Special Issue: Liver-Lung Syndromes
Volume 4, Issue 1
Special Issue: Drug-Induced Liver Injury (DILI)
New Issue: Procedures for the Liver Patient
Before exploring the issue, test yourself on "Procedures for the Liver Patient"
Keyur Patel, M.D., and Julius Wilder, M.D., Ph.D.
Transient elastography (FibroScan) is an ultrasound-based technique initially developed by the food industry to assess the maturity of cheese, but it's also an accurate and safe method to measure the severity of fibrosis in chronic liver disease.
Abba Zubair, M.D., Ph.D.
Therapeutic phlebotomy is indicated as an integral component of the treatment of several medical conditions, and it's the cheapest and most effective method for removing excess iron in nonanemic patients.
Colonoscopy in Liver Disease
Shiva K Ratuapli M.D., Hugo E. Vargas M.D.
Colonoscopy is an endoscopic procedure performed by passing a flexible scope with a camera from the anus to the cecum and terminal ileum, and is performed for both diagnostic and therapeutic purposes - learn about the indications for colonoscopy in liver disease.
Remy Schwarzer, M.D., and Arnulf Ferlitsch, M.D., Ph.D
Liver biopsy was developed in 1884 and remains a cornerstone for diagnosing liver disease. Transjugular liver biopsy (TJLB) was introduced about 80 years later - learn about the pros and cons of each technique.
Upper Endoscopy in Liver Disease
Kaci Christian, M.D., Matthew Hudson, M.D., and Eric Goldberg, M.D.
EGD is an endoscopic procedure that affords views of the esophagus, stomach, and proximal duodenum. Although EGD has a broad role in general GI complaints, it has several applications specific to patients with chronic liver disease.
Primer on Magnetic Resonance Imaging of the Liver
Peter Bannas, M.D., Utaroh Motosugi, M.D., Shintaro Ichikawa, M.D., Diego Hernando, Ph.D., and Scott B. Reeder, M.D., Ph.D.
Over the past decade, MRI has emerged as a powerful clinical tool for liver imaging, but the multitude of pulse sequences and contrast agents that have made it increasingly complex. What do you need to know to use MRI effectively?
Series on New Treatments for Hepatitis C
Guest Edited by Donald M. Jensen, M.D., F.A.C.P.
The Dawn of a New Era in the Treatment of HCV infection: A View from the USA
Paul J. Pockros, MD
Get a snapshot of HCV therapy from the vantage point of US physicians. In the coming months, we’ll publish similar personal perspectives on the treatment of HCV in the new era from the viewpoint of providers in South America, Europe, and Asia.
More recent articles on HCV:
HCV Treatment of Special Populations:
HIV Coinfected, Liver Transplant, and Renal Failure
Nadeem Anwar, M.D., and Kenneth E. Sherman, M.D., Ph.D.
With new recommendations regarding birth cohort screening, more and more people will be diagnosed and referred for HCV treatment. Even in the new era of DAA therapy, some populations still require special consideration - learn more from Drs. Anwar and Sherman.
HCV Testing and Linkage to Care:
Nancy Reau, M.D.
The limitation to HCV therapy is not treatment efficacy; it's identification of patients and linking them to providers interested in delivering antiviral therapy. Where does the system break down? Dr. Nancy Reau investigates.
New All-Oral HCV Therapies for Genotype 1: A Final Good-bye to Interferon
Anna S.F. Lok, M.D.
With more than 30 direct-acting antiviral agents (DAAs) in clinical trials, the hepatitis C community anticipates that the right combinations of DAAs will emerge, permitting treatment of hepatitis C virus (HCV) genotype 1 with interferon (IFN)-free regimens.
For more information related to HCV genotypes, read:
Goossens N, Negro F. Is genotype 3 of hepatitis C virus the new villian? Hepatology. 59:6, 2403–2412, June 2014.
New AASLD/IDSA HCV Practice Guidelines: An Online Resource
Gary L. Davis, M.D.
As treatment for Hepatitis C rapidly evolves, how are recommendations being developed, and how they will be updated over time? Read or listen to Dr. Gary Davis' review to learn more about how organiziations like the AASLD are working to keep clinicians informed with the best and most up-to-date guidelines.
Recent FDA Approval of Sofosbuvir and Simeprevir. Implications for Current HCV Treatment
M. Valerie Lin, M.D., and Raymond Chung, M.D.
Drs. Lin and Chung break down what clinicians need to know about Sofosbuvir and Simeprevir: from mechanisms of action, to approved indications, use outside approved indications, and treatment challenges.